Novartis, Sandoz Recall Entacapone Products over Carcinogenic Risk

Novartis Pharma and Sandoz on March 22 launched voluntary recalls for their respective products containing entacapone after detecting an excessive level of potentially carcinogenic nitrosamine impurities. Subject to the recalls, both categorized as Class II, are some batches of Novartis’...read more